KEYWORD INDEX

#

3D co-culture	A027

A

Acquired Resistance	A023
Adjuvant immunotherapy	A010
Adoptive immunotherapy	A013
AKT	A033
alcoholic liver disease	A047
APOB	A032
Apoptosis	A045
Atezolizumab-bevacizumab	A020

B

BHMC	A045
Biomarkers	A017

C

cancer immunotherapy	A014
Cancer-associated fibroblasts	A020, A051
CAR T cells	A024
CAR/TCR-T cell therapy	A006
CAR-T cell therapy	A012
CAR-T in silico platform	A012
casdatifan	A021
Cellular Therapy, Hepatocellular carcinoma, Computational Transcriptomic	A028
cholangiocarcinoma	A044
Cholangiocarcinoma	A051
Circulating tumor DNA	A007
Cirrhosis	A019
CKMT1, Mitochondrial creatine kinase	A044
Clonal evolution	A009
Computational surgery	A008, A010
Creatine metabolism, SLC6A8, HCC	A044
CRISPR gene editing	A043

KEYWORD INDEX

ctDNA A003
cytokines A047, A052

D

Dendritic cells A030
Dietary protein restriction A042

E

EGFR inhibitors A049
entosis A038
Environmental carcinogenesis A050
Environmental hepatotoxicity A050

F

FGF19 A025
FGFR4 A025
Fibrolamellar A002, A004
fibrolammellar A005
Fibrolammellar A003
Frizzled receptor A015

G

G6PD A035
Glutamine synthesis A042
Glypican-3 A024

H

HCC A016, A031
HCC immunotherapy A011
HCC modeling A043
Hepatitis B A041
Hepatoblastoma A001
hepatocellular carcinoma A038
Hepatocellular carcinoma A008, A010, A024, A027, A032, A049, A050
Hepatocellular Carcinoma A023, A041, A048

KEYWORD INDEX

Hepatocellular carcinoma (HCC) A013, A054
Hepatocellular carcinoma, Immune checkpoint inhibitors, Neurologic adverse events A029
Hepatocellular carcinoma, β-catenin, immune exclusion A022
Hepatocytes A039
HepG2 A045
HIF-2α A021

I

ICI resistance A019
ICIs A053
IDH1 A044
Immune Checkpoint A051
immune system A046
immuno-chemotherapy A005
immunotherapy A016
Immunotherapy A004, A008, A017, A053
Immunotherapy A052
Immunotherapy, TME, Liver Cancer Stem Cells A036
inflammation A052

J

There were no keywords in this range.

K

Kupffer cell A022

L

LAP1 A039
large language model (LLM) A012
liver cancer A014
Liver Fibrosis A031, A048
locoregional therapies A038

M

macrophages A011
MASH A031

KEYWORD INDEX

MASH-HCC, Immunosurveillance, neoantigens A030
MASH-HCC, immunotherapy, TGF-ß A018
MASH-Related HCC A035
MASLD A048
MASLD-HCC A053
MET, MYC A022
Metabolic dysfunction-associated steatohepatitis (MASH) , Kupffer cells , ID1 A040
Metabolic vulnerabilities A027
Metastasis A001
metastatic A005
Methylation A039
mRNA vaccine A006
Mucosal-associated invariant T (MAIT) A013
Mucosal-associated invariant T (MAIT) cell A014

N

Nanobody, AI drug discovery, Wnt siganling, A015
nutrition A047

O

oncogene A046

P

Perfusion kinetics A007
Phosphoproteomics A033
Physics-informed neural networks A007
predictive biomarkers A019
Primary human hepatocytes A043
Protein A041
PTEN A033
Pyridine heterocycles A049

Q

There were no keywords in this range.

R

KEYWORD INDEX

resistance A044
Response A003
RGX-202 A044

S

single-cell RNA sequencing A034
small molecule inhibition A021
Spatial heterogeneity A009
Spatial Transcriptomics A016
sphingolipids A011
STEAP2, Self-delivering Antisense Oligonucleotide,TGF-β, SMAD A026
Subclonal Heterogeneity A023
Surgical margin A009
Survival A002

T

Targeted therapy A025
TGF-beta signaling A032
Tocilizumab A004
Transforming Growth Factor Beta (TGFβ) A020
Transplantation A002
TREM1, MDSC, Kupffer Cells A036
tumor immune microenvironment A034
tumor-associated macrophages A034

U

Universal shared cancer antigens A006
Urea cycle A042

V

VJDT, Cobinational Therapy, TME remodelling A036

W

Wsx1 A046

X

KEYWORD INDEX

Xenium A001

Y

There were no keywords in this range.

Z

There were no keywords in this range.